# MAQ-001

Source: https://onco.cc/drugs/maq-001/  
OnCo record `maq-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MAQ-001 is an experimental monoclonal antibody from MabQuest, in phase 1 trials for advanced solid tumours.

## Summary

MAQ-001 is a monoclonal antibody (allosteric anti-PD-1) from MabQuest. An anti-PD-1 antibody that binds PD-1 at an allosteric site; it stops PD-1 from suppressing the CD28 co-receptor, independent of PD-L1 binding, and is meant to be combined with conventional anti-PD-1 and other checkpoint drugs. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT06514651 recruiting in France, alone and with ipilimumab. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: MAQ-001
- Modality: Monoclonal antibody (allosteric anti-PD-1)
- Mechanism: An anti-PD-1 antibody that binds PD-1 at an allosteric site; it stops PD-1 from suppressing the CD28 co-receptor, independent of PD-L1 binding, and is meant to be combined with conventional anti-PD-1 and other checkpoint drugs.

## Sources

- MabQuest: mabquest.co: https://mabquest.co/what-we-do
- MabQuest: mabquest.co: https://mabquest.co/what-we-do
- MabQuest: mabquest.co: https://mabquest.co/what-we-do
- MabQuest: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06514651
- ClinicalTrials.gov: trials of MAQ-001: https://clinicaltrials.gov/search?intr=MAQ-001

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- companies: [MabQuest](https://onco.cc/companies/mabquest/)
- trials: [MAQ-001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06514651/)

---
JSON: https://onco.cc/api/v1/entities/maq-001.json